Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shin Nippon Biomedical Laboratories (SNBL) has announced a collaboration with Astellas Pharma to enhance the drug discovery ecosystem in Tsukuba City by providing non-clinical study support at the SakuLab™-Tsukuba innovation center. SNBL, Japan’s largest nonclinical CRO, will offer its expertise in drug discovery to support startups, academia, and pharmaceutical companies at Tsukuba, one of Japan’s leading life science centers. This partnership aims to accelerate the development of new drugs and advanced technologies within the Tsukuba ecosystem.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.